Stephanie Davis
Stock Analyst at Barclays
(0.86)
# 2,682
Out of 4,479 analysts
83
Total ratings
31.37%
Success rate
-17.78%
Average return
Main Sectors:
19 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACCD Accolade | Maintains: Equal-Weight | $11 → $5.5 | $3.53 | +55.81% | 8 | Jun 28, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $9 → $10 | $7.82 | +27.88% | 6 | May 20, 2024 | |
| LH Labcorp Holdings | Maintains: Equal-Weight | $234 → $213 | $202.73 | +5.07% | 2 | Apr 26, 2024 | |
| DGX Quest Diagnostics | Maintains: Equal-Weight | $138 → $144 | $136.64 | +5.39% | 1 | Apr 25, 2024 | |
| WW WW International | Maintains: Underweight | $8 → $1.5 | $1.13 | +33.33% | 1 | Mar 1, 2024 | |
| RCM R1 RCM | Downgrades: Equal-Weight | $14 | $10.90 | +28.44% | 4 | Feb 28, 2024 | |
| TALK Talkspace | Maintains: Equal-Weight | $2.5 → $3 | $2.18 | +37.61% | 6 | Feb 23, 2024 | |
| OPRX OptimizeRx | Initiates: Equal-Weight | $15 | $10.07 | +48.96% | 1 | Jan 3, 2024 | |
| PHR Phreesia | Initiates: Overweight | $29 | $20.50 | +41.46% | 11 | Jan 3, 2024 | |
| MDRX Veradigm | Initiates: Equal-Weight | $11 | $9.66 | +13.87% | 8 | Jan 3, 2024 | |
| COR Cencora | Initiates: Overweight | $242 | $222.51 | +8.76% | 1 | Jan 3, 2024 | |
| CAH Cardinal Health | Initiates: Overweight | $117 | $96.54 | +21.19% | 1 | Jan 3, 2024 | |
| TDOC Teladoc Health | Upgrades: Outperform | $34 | $9.40 | +261.70% | 8 | Feb 23, 2023 | |
| PINC Premier | Maintains: Outperform | $46 → $42 | $18.50 | +127.03% | 2 | Feb 8, 2023 | |
| PGNY Progyny | Downgrades: Market Perform | $59 → $34 | $28.33 | +20.01% | 3 | Jan 5, 2023 | |
| VEEV Veeva Systems | Maintains: Outperform | $242 → $233 | $182.85 | +27.43% | 8 | Dec 2, 2022 | |
| HCAT Health Catalyst | Maintains: Outperform | $20 → $17 | $6.10 | +178.69% | 8 | Nov 9, 2022 | |
| HQY HealthEquity | Maintains: Outperform | $67 → $76 | $85.76 | -11.38% | 2 | Jun 7, 2022 | |
| DOCS Doximity | Maintains: Outperform | $72 → $67 | $26.96 | +148.52% | 2 | May 18, 2022 |
Accolade
Jun 28, 2024
Maintains: Equal-Weight
Price Target: $11 → $5.5
Current: $3.53
Upside: +55.81%
GoodRx Holdings
May 20, 2024
Maintains: Overweight
Price Target: $9 → $10
Current: $7.82
Upside: +27.88%
Labcorp Holdings
Apr 26, 2024
Maintains: Equal-Weight
Price Target: $234 → $213
Current: $202.73
Upside: +5.07%
Quest Diagnostics
Apr 25, 2024
Maintains: Equal-Weight
Price Target: $138 → $144
Current: $136.64
Upside: +5.39%
WW International
Mar 1, 2024
Maintains: Underweight
Price Target: $8 → $1.5
Current: $1.13
Upside: +33.33%
R1 RCM
Feb 28, 2024
Downgrades: Equal-Weight
Price Target: $14
Current: $10.90
Upside: +28.44%
Talkspace
Feb 23, 2024
Maintains: Equal-Weight
Price Target: $2.5 → $3
Current: $2.18
Upside: +37.61%
OptimizeRx
Jan 3, 2024
Initiates: Equal-Weight
Price Target: $15
Current: $10.07
Upside: +48.96%
Phreesia
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $20.50
Upside: +41.46%
Veradigm
Jan 3, 2024
Initiates: Equal-Weight
Price Target: $11
Current: $9.66
Upside: +13.87%
Cencora
Jan 3, 2024
Initiates: Overweight
Price Target: $242
Current: $222.51
Upside: +8.76%
Cardinal Health
Jan 3, 2024
Initiates: Overweight
Price Target: $117
Current: $96.54
Upside: +21.19%
Teladoc Health
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $9.40
Upside: +261.70%
Premier
Feb 8, 2023
Maintains: Outperform
Price Target: $46 → $42
Current: $18.50
Upside: +127.03%
Progyny
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $28.33
Upside: +20.01%
Veeva Systems
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $182.85
Upside: +27.43%
Health Catalyst
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $6.10
Upside: +178.69%
HealthEquity
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $85.76
Upside: -11.38%
Doximity
May 18, 2022
Maintains: Outperform
Price Target: $72 → $67
Current: $26.96
Upside: +148.52%